Studies have found that gastrointestinal selective TPH inhibitors can manage several gastrointestinal diseases [40], inhibiting mucosal 5-HT production alleviates inflammation [41], and microbial short-chain fatty acids (SCFAs) can promote the TPH1 transcription of enterochromaffin cells and the production of colon 5-HT and stimulate colon transport [42]. The gene discussed is TPH1; the disease is gastrointestinal disease.